GlaxoSmithKline (LON: GSK, NYSE: GSK), the UK-based pharmaceutical giant, has this week released long-term data from a follow-up Phase III trial of its recombinant herpes zoster vaccine, Shingrix. The vaccine demonstrated robust efficacy in adults aged 50 and above, with a 79.7% efficacy rate sustained from year 6 to year 11 post-initial vaccination. Notably, at year 11, the efficacy rate held up at 82.0%, and among participants aged 70 and above, the vaccine showed a 73.1% efficacy rate between years 6 and 11.
These results indicate that Shingrix provides enduring protection for several years across various age groups. Moving forward, GSK intends to evaluate the potential necessity for a booster dose, utilizing both long-term clinical data and real-world evidence to inform its decision-making process.- Flcube.com
